Primary Objective: To assess the benefit of using nebulized tranexamic acid versus the standard of care on 28 day mortality.~Secondary Objectives: To assess the following outcomes when using nebulized tranexamic acid versus the standard of care:~90 day, ICU and hospital mortality rate~Ventilator days at day 28~ICU and Hospital Length of Stay~PaO2:FIO2 ratio (or SpO2:FIO2 ratio) changes over the first 14 days~Time to resolution of pulmonary hemorrhage~Rate of recurrence of pulmonary hemorrhage~Rate of invasive procedures required to control pulmonary hemorrhage~Changes in Lung Injury Score over the first 14 days following randomization
This is a drug study that will examine if inhaled tranexamic acid can improve mortality in patients with cancer-related pulmonary hemorrhage and respiratory failure as compared to usual care.